The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.

The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.

The present invention provides a coating formation method with which adhesion between skin and a coating formed by electrostatic spraying is enhanced. The coating formation method of the present invention includes a liquid agent applying step of applying a liquid agent containing one or more selected from water, polyols and oils that are in a liquid form at 20° C., and an electrostatic spraying step of electrostatically spraying a composition directly on skin to form a coating. The liquid agent applying step and the electrostatic spraying step are performed in this order or in a reversed order. The composition includes a component (a) and a component (b) below: (a) one or more volatile substances selected from the group consisting of water, alcohols, and ketones, and (b) a polymer having a coating formation ability.

The present invention provides a coating formation method with which adhesion between skin and a coating formed by electrostatic spraying is enhanced. The coating formation method of the present invention includes a liquid agent applying step of applying a liquid agent containing one or more selected from water, polyols and oils that are in a liquid form at 20° C., and an electrostatic spraying step of electrostatically spraying a composition directly on skin to form a coating. The liquid agent applying step and the electrostatic spraying step are performed in this order or in a reversed order. The composition includes a component (a) and a component (b) below: (a) one or more volatile substances selected from the group consisting of water, alcohols, and ketones, and (b) a polymer having a coating formation ability.

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

Injectable prolonged-action compositions for use in the treatment of nail diseases, including potentially promoting the growth of the nail, or for use promoting the growth of the nail. The compositions are administered subcutaneously, and optionally as an implant. The compositions may be in solid or non-solid form and include one or more solid biodegradable sustained-release polymers, and optionally one or more active substances.

The present disclosure relates generally to compositions that include at least two or at least three gelling agents, at least one emollient, and at least 15% water by mass relative to the total mass.

The present disclosure relates generally to compositions that include at least two or at least three gelling agents, at least one emollient, and at least 15% water by mass relative to the total mass.

An external skin preparation comprises the following components (A) to (E), wherein the mass ratio of the component (A) to the component (B), (A)/(B), is from 0.3 to 2.0, wherein the content of the component (C) is from 0.1 to 1 mass %, and wherein the preparation has a pH at 25° C. of from 4.0 to 7.0: (A) one or more selected from the group consisting of aliphatic alcohols having from 14 to 20 carbon atoms; (B) two or more selected from the group consisting of polyhydric alcohol fatty acid ester-type nonionic surfactants; (C) one or more selected from the group consisting of N-acyl amino acids, N-acyl taurine, salts thereof, and phospholipids; (D) one or more selected from the group consisting of steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, and heparinoids; and (E) water.